precursor
plasmid
vaccin
construct
bp
encod
gag
gene
strain
tabl
briefli
built
plasmid
backbon
contain
kanamycin
resist
gene
human
cytomegaloviru
cmv
promoterenhanc
contain
immedi
earli
untransl
region
intron
bovin
growth
hormon
bgh
polyadenyl
sequenc
backbon
differ
relat
backbon
hartikka
et
al
use
product
describ
remov
xmni
site
region
follow
bgh
poli
sequenc
replac
sfii
site
done
ensur
least
one
sfii
site
present
plasmid
construct
permit
use
sfii
integr
studi
gene
insert
contain
sfii
site
backbon
use
backbon
introduc
sfii
site
use
synthet
version
gag
gene
use
codon
optim
express
human
cell
insert
plasmid
backbon
nucleotid
sequenc
synthet
gag
gene
show
littl
homolog
gene
protein
encod
candid
vaccin
enter
clinic
trial
develop
multigen
construct
pursu
instead
firstgener
plasmid
vaccin
candid
bp
gener
insert
plasmid
backbon
synthet
human
gag
gene
strain
ligat
frame
sequenc
encod
synthet
human
codon
optim
pol
polyprotein
strain
allow
natur
translat
frameshift
synthet
code
region
last
four
amino
acid
nucleocapsid
protein
rest
gag
plu
addit
three
amino
acid
pol
replac
authent
viral
sequenc
introduc
site
requir
frameshift
restor
abil
express
gag
protein
mutat
introduc
proteas
rt
integraseencod
sequenc
destroy
biolog
activ
viral
protein
safeti
retain
maxim
number
potenti
epitop
immunogen
inocul
human
vaccin
candid
huang
et
al
phase
trial
product
complet
product
also
serv
compar
plasmid
later
product
test
biodistribut
studi
product
combin
two
plasmid
bp
consist
clade
b
env
gene
insert
backbon
describ
env
gene
contain
follow
modif
human
sequenc
sequenc
bal
insert
chang
tropism
receptor
receptor
chimer
env
gene
truncat
includ
entir
su
region
portion
tm
includ
fusion
domain
transmembran
domain
region
import
oligomer
portion
fusioncleavag
domain
delet
interspac
heptad
version
env
refer
chakrabarti
et
al
bp
encod
human
gag
pol
nef
gene
express
fusion
protein
delet
introduc
proteas
rt
integrasecod
region
destroy
biolog
activ
viral
protein
safeti
reason
addit
authent
viral
sequenc
includ
region
allow
frameshift
describ
product
gag
portion
fusion
protein
strain
pol
nef
portion
strain
entir
nef
includ
initi
atg
includ
construct
insert
backbon
clade
b
combin
product
test
clinic
trial
multiclad
approach
chosen
clinic
develop
howev
two
compon
vaccin
candid
includ
among
compon
product
proceed
clinic
trial
see
descript
product
detail
product
combin
two
plasmid
compon
product
describ
product
describ
clade
b
product
also
proceed
clinic
trial
multiclad
approach
chosen
clinic
develop
bp
encod
fusion
protein
human
insert
backbon
entir
code
region
human
cdna
includ
nativ
sequenc
without
mutat
fc
portion
human
barouch
et
al
product
combin
six
plasmid
clade
b
env
gene
clade
b
gagpolnef
describ
product
bp
consist
human
gene
encod
gagpolnef
fusion
protein
modifi
describ
clade
c
sequenc
identifi
genbank
access
number
stop
codon
tag
remov
gagpol
gene
nef
gene
viru
ligat
fusion
sequenc
insert
backbon
bp
consist
human
gene
encod
env
protein
modifi
describ
clade
c
strain
insert
backbon
bp
consist
human
gene
encod
gagpolnef
fusion
protein
modifi
describ
clade
strain
identifi
genbank
access
number
gagpol
nef
insert
backbon
bp
consist
human
gene
encod
env
protein
modifi
describ
clade
strain
insert
backbon
product
proceed
clinic
trial
although
product
consist
four
six
plasmid
contain
product
test
complet
phase
trial
test
ongo
phase
trial
basi
decid
clinic
develop
fourplasmid
product
instead
product
result
murin
kong
et
al
nonhuman
primat
nhp
unpublish
data
immunogen
studi
nhp
studi
led
develop
anoth
sixplasmid
product
contain
cmvr
promot
see
product
ebola
descript
separ
gag
pol
nef
onto
separ
plasmid
barouch
et
al
preclin
studi
describ
herein
companion
articl
product
well
product
ebola
along
phase
clinic
data
support
develop
newer
gener
sixplasmid
product
also
enter
phase
test
martin
et
al
proceed
advanc
clinic
develop
prime
adenoviru
type
boost
hiv
vaccin
regimen
firstgener
ebola
product
sullivan
et
al
xu
et
al
consist
combin
four
plasmid
bp
consist
synthet
human
gene
express
nucleoprotein
np
zair
strain
ebola
viru
insert
backbon
bp
consist
synthet
human
gene
express
fulllength
glycoprotein
gp
sudan
strain
ebola
viru
insert
backbon
bp
consist
synthet
human
gene
express
fulllength
gp
protein
ivori
coast
strain
ebola
viru
insert
backbon
bp
consist
synthet
human
gene
express
fulllength
gp
protein
zair
strain
ebola
viru
insert
backbon
howev
product
proceed
clinic
trial
observ
vitro
cytotox
fulllength
gp
construct
sullivan
et
al
theoret
safeti
concern
phenomenon
rais
modifi
gp
vector
develop
secondgener
ebola
product
consist
combin
three
plasmid
backbon
refer
cmvr
use
plasmid
differ
plasmid
backbon
substitut
human
tlymphotroph
viru
long
termin
repeat
ltr
region
cmv
immedi
earli
region
enhanc
improv
gene
express
barouch
et
al
bp
consist
synthet
human
gene
express
np
protein
zair
strain
ebola
viru
bp
consist
synthet
human
gene
express
transmembranedelet
gp
protein
zair
strain
ebola
viru
bp
consist
synthet
human
gene
express
transmembranedelet
gp
protein
sudangulu
strain
ebola
viru
phase
trial
product
complet
repres
first
clinic
trial
ebola
viru
vaccin
candid
world
bp
encod
human
gene
express
glycoprotein
urbani
strain
sar
cmvr
backbon
describ
transmembran
region
portion
cytoplasm
domain
includ
yang
et
al
firstgener
sar
product
test
ongo
clinic
trial
repres
first
sar
vaccin
candid
test
clinic
trial
unit
state
bp
encod
human
wnv
prem
e
protein
gene
strain
backbon
addit
leader
sequenc
also
human
codon
optim
isol
japanes
enceph
viru
includ
firstgener
wnv
test
ongo
human
clinic
trial
earlier
studi
involv
comparison
dna
plasmid
vaccin
us
navi
malaria
program
previous
test
preclin
clinic
product
briefli
describ
epstein
et
al
later
studi
involv
comparison
product
describ
mani
studi
perform
biojector
refer
hereaft
biojector
devic
needleless
inject
system
clear
fda
im
sc
inject
liquid
medic
includ
vaccin
liquid
vaccin
forc
tini
orific
held
skin
creat
fine
highpressur
stream
penetr
skin
deposit
vaccin
tissu
beneath
system
three
compon
reusabl
devic
steril
singleus
dispos
needlefre
syring
cartridg
earlier
studi
mice
perform
needl
syring
precis
devic
use
clinic
trial
suitabl
size
speci
without
modif
differ
group
anim
inocul
biodistribut
studi
repeateddos
toxicolog
studi
follow
reason
biodistribut
analys
anim
inocul
determin
inoculum
subsequ
biodistribut
wherea
repeateddos
toxicolog
studi
anim
repeatedli
dose
time
termin
biodistribut
studi
gener
week
month
postinocul
markedli
differ
repeateddos
inocul
time
termin
gener
day
week
last
inocul
repeateddos
toxicolog
studi
studi
b
c
perform
bioreli
rockvil
md
involv
inocul
male
nonpregn
femal
hsd
icr
mice
mcg
order
molecul
dna
plasmid
vaccin
either
im
iv
data
shown
rout
compar
inocul
phosphatebuff
salin
pb
rout
anim
inocul
one
time
point
five
anim
per
gender
per
inocul
rout
test
articl
one
anim
per
gender
per
inocul
rout
control
termin
studi
day
follow
organ
collect
biodistribut
analys
gonad
brain
kidney
mesenter
lymph
node
lung
liver
right
thigh
muscl
inject
site
case
im
inocul
bone
marrow
left
femur
heart
blood
tissu
snap
frozen
liquid
nitrogen
place
steril
vial
addit
tissu
collect
biodistribut
anim
monitor
morbid
mortal
twice
daili
clinic
sign
toxic
bodi
posit
locomotor
activ
secret
eye
nose
mouth
coat
condit
respir
excret
muscl
tone
bodi
tremor
daili
data
shown
bodi
weight
measur
day
prior
termin
data
shown
gross
patholog
observ
termin
data
shown
studi
perform
complianc
good
laboratori
practic
glp
regul
cfr
studi
e
f
g
perform
genelog
formerli
therimmun
involv
inocul
new
zealand
white
rabbit
mg
moder
human
dose
order
molecul
dna
plasmid
deliv
im
biojector
needleless
inject
devic
method
also
use
inject
candid
vaccin
clinic
studi
studi
comparison
made
pb
compar
plasmid
malaria
studi
studi
e
f
g
prior
biodistribut
toxicolog
integr
data
well
clinic
safeti
data
anim
inocul
one
time
point
termin
sodium
thiopent
inject
studi
nembut
sodium
inject
studi
f
g
sodium
pentobarbit
inject
studi
e
exsanguin
day
varianc
studi
day
termin
studi
base
pragmat
schedul
consider
anim
facil
time
point
approximatli
week
month
postinocul
studi
day
design
studi
consist
fda
recommend
current
time
studi
initi
well
refin
protocol
experi
gain
vrc
follow
organ
collect
biodistribut
analys
blood
gonad
liver
thymu
studi
f
g
heart
lung
adren
gland
studi
f
g
kidney
spleen
mesenter
lymph
node
studi
right
left
poplit
lymph
node
collect
separ
studi
f
g
contralater
poplit
lymph
node
studi
e
subcuti
inject
site
thigh
muscl
inject
site
bone
marrow
left
femur
studi
f
g
brain
pair
organ
process
togeth
tissu
bone
marrow
cell
snap
frozen
liquid
nitrogen
place
steril
vial
store
addit
anim
monitor
morbid
tremor
convuls
saliv
diarrhea
lethargi
coma
atyp
behavior
mortal
twice
daili
clinic
sign
toxic
evalu
skin
fur
characterist
eye
mucou
membran
respiratori
circulatori
automon
central
nervou
system
somatomotor
behavior
pattern
prior
dose
weekli
termin
data
shown
bodi
weight
taken
prior
dose
weekli
termin
fast
food
consumpt
measur
daili
data
shown
studi
perform
complianc
glp
regul
studi
h
perform
univers
michigan
inlif
portion
althea
technolog
inc
san
diego
ca
dna
extract
pcr
analysi
involv
inocul
femal
mice
n
studi
h
n
studi
mcg
split
two
site
per
anim
im
right
left
quadricep
muscl
day
postinocul
inject
muscl
tissu
harvest
specimen
pool
right
muscl
togeth
left
muscl
togeth
minc
place
extract
buffer
mgml
proteinas
k
tri
ph
edta
nacl
tween
incub
overnight
dnasefre
rnase
mgml
ad
incub
min
specimen
extract
three
time
equal
volum
buffer
phenol
chloroform
dna
precipit
two
volum
ethanol
room
temperatur
dna
pellet
rins
ethanol
airdri
room
temperatur
pellet
resuspend
ml
tri
ph
concentr
determin
uv
spectrophotomet
thirti
mcg
right
left
quadricep
muscl
dna
load
agaros
tube
gel
total
mcg
gel
run
v
use
fieldinvers
gel
electrophoresi
h
use
bacteriophag
lambda
cut
hindiii
kpni
size
marker
pool
purifi
specimen
use
pcr
analysi
addit
purifi
dna
digest
unit
sfiimcg
dna
overnight
digest
dna
precipit
subject
second
round
purif
mcg
total
dna
pool
specimen
extract
gel
use
pcr
analysi
studi
conduct
complianc
glp
research
studi
genom
dna
gdna
isol
tissu
use
promega
wizard
genom
dna
purif
kit
dna
dilut
steril
nucleasefre
water
final
concentr
mcgmcl
use
ten
mcl
sampl
test
per
pcr
reaction
gener
mg
tissu
process
dna
extract
tissu
physic
homogen
subject
digest
proteinas
k
dna
extract
biorobot
workstat
qiagen
valencia
ca
use
reagent
protocol
recommend
manufactur
tissu
sampl
includ
run
biorobot
serv
sentinel
control
contamin
concentr
elut
dna
determin
uv
spectrophotometri
adjust
final
concentr
suitabl
quantit
pcr
qpcr
realtim
quantit
modif
taqman
pcr
techniqu
amplicon
detect
sequencespecif
fluorogen
probe
use
primer
probe
select
use
primer
express
primer
design
softwar
pe
appli
biosystem
foster
citi
ca
forward
primer
use
revers
primer
probe
label
report
dye
pe
appli
biosystem
foster
citi
ca
amplif
target
sequenc
perform
abi
prism
sequenc
detector
system
use
univers
taqman
buffer
contain
amperas
ung
amplitaq
gold
dna
polymeras
primer
final
concentr
probe
tissu
separ
spike
copi
plasmid
interest
monitor
qpcr
inhibit
control
dna
neg
control
mous
gdna
spike
control
standard
curv
two
seri
templat
dilut
plasmid
interest
copi
also
run
assay
perform
characterist
establish
follow
valu
less
one
copi
consid
biolog
relev
score
neg
limit
detect
lod
assay
consid
copi
limit
quantit
loq
bound
linear
rang
assay
consid
copi
specimen
score
posit
therefor
valu
one
nine
copi
regard
nonquantifi
qpcr
studi
b
c
perform
bioreli
taqman
qpcr
assay
design
target
bovin
growth
hormon
polyadenyl
signal
sequenc
element
common
plasmid
backbon
construct
primer
probe
design
use
primer
express
softwar
appli
biosystem
inc
foster
citi
ca
forward
primer
use
revers
primer
probe
taqman
reaction
perform
plate
use
abi
prism
instrument
amplif
target
sequenc
perform
duplic
reaction
contain
gdna
tissu
taqman
univers
pcr
master
mix
appli
biosystem
foster
citi
ca
primer
probe
final
concentr
respect
third
replic
reaction
perform
spike
copi
target
sequenc
monitor
qpcr
inhibit
cycl
condit
min
min
cycl
min
quantif
target
sequenc
specimen
determin
use
standard
curv
plasmid
dna
dilut
background
gdna
isol
anim
standard
control
contain
templat
sentinel
extract
control
background
gdna
control
run
duplic
reaction
assay
perform
characterist
establish
assay
qualifi
use
transgen
insert
anim
model
lod
assay
copi
target
sequenc
gdna
extract
tissu
loq
assay
copi
target
sequencemcg
gdna
extract
tissu
qpcr
analys
studi
e
f
g
h
j
perform
althea
technolog
inc
wilcoxon
ranksum
test
use
compar
distribut
first
last
time
point
twosid
p
valu
procedur
report
test
articl
use
thigh
muscl
subcuti
data
avail
read
report
lod
loq
set
valu
limit
insert
use
nonparametr
rankbas
test
allow
discret
observ
includ
comparison
distribut
adjust
two
comparison
site
threshold
use
cutoff
statist
signific
larger
p
valu
simpli
report
signific
graphic
display
data
transform
use
logarithm
due
strongli
skew
distribut
nonconst
varianc
four
group
inocul
studi
two
group
receiv
pb
either
iv
data
shown
im
two
group
receiv
mcg
either
iv
data
shown
im
pcr
statist
analysi
result
shown
figur
andor
tabl
four
group
inocul
studi
two
group
receiv
pb
either
iv
data
shown
im
two
group
receiv
mcg
product
either
iv
data
shown
im
pcr
statist
analysi
result
shown
figur
andor
tabl
four
group
inocul
studi
two
group
receiv
pb
either
iv
data
shown
im
two
group
receiv
mcg
product
ebola
either
iv
data
shown
im
pcr
statist
analysi
result
shown
figur
andor
tabl
four
group
inocul
studi
one
group
receiv
pb
one
group
receiv
mg
product
adjuv
product
cytokin
adjuv
test
articl
one
group
receiv
mg
product
test
articl
one
group
receiv
mg
control
plasmid
malaria
pcr
statist
analys
result
shown
figur
andor
tabl
three
group
inocul
studi
one
group
receiv
pb
one
group
receiv
mg
product
ebola
final
group
receiv
mg
product
compar
plasmid
pcr
statist
analys
result
shown
figur
andor
tabl
three
group
inocul
studi
one
group
receiv
pb
one
group
receiv
mg
product
sar
final
group
receiv
mg
product
compar
plasmid
pcr
statist
analys
result
shown
figur
andor
tabl
three
group
inocul
studi
one
group
receiv
pb
one
group
receiv
mg
product
wnv
final
group
receiv
mg
product
compar
plasmid
pcr
statist
analys
result
shown
figur
andor
tabl
target
dna
detect
dna
extract
pool
inject
site
specimen
prior
separ
purif
highmolecular
weight
dna
target
detect
either
primari
secondari
highmolecular
weight
dna
separ
purif
thu
five
copi
plasmid
dna
could
integr
mcg
highmolecular
weight
mous
gdna
neg
result
conclud
lack
integr
cours
studi
consist
pattern
biodistribut
confin
site
inject
clearanc
observ
dna
plasmid
vaccin
dose
mg
inocul
im
needl
syring
biojector
regardless
express
gene
insert
promot
plasmid
backbon
use
drive
express
studi
demonstr
plasmid
vaccin
wide
biodistribut
remain
site
inject
muscl
overli
subcuti
differ
note
biodistribut
clearanc
pattern
gender
furthermor
plasmid
dna
virtual
never
found
gonad
specimen
sporad
case
signal
seen
low
often
nonquantifi
could
result
inadvert
contamin
cours
collect
tissu
necropsi
despit
scrupul
effort
avoid
find
allay
theoret
concern
voic
potenti
plasmid
vaccin
product
biodistribut
reproduct
organ
although
rigor
measur
undertaken
prevent
crosscontamin
chang
glove
equip
etc
pcr
readout
exquisit
sensit
smallest
contamin
necropsi
tissu
collect
would
detect
fact
seem
like
sporad
posit
tissu
ie
tissu
muscl
subcuti
site
inject
indic
biodistribut
dna
plasmid
tissu
rather
result
unavoid
lowlevel
contamin
altern
fals
posit
assay
limit
use
exquisit
sensit
readout
addit
studi
demonstr
plasmid
vaccin
candid
clear
rel
rapidli
although
molecul
inocul
studi
rabbit
even
day
week
postinocul
order
copi
per
microgram
dna
extract
tissu
alreadi
clear
site
inject
cours
month
inoculum
clear
muscl
anim
anim
signal
remain
gener
subcuti
copi
number
order
per
microgram
dna
extract
tissu
point
data
explain
plasmid
remain
subcutisskin
muscl
receiv
bolu
inoculum
howev
phenomenon
seen
consist
data
other
person
commun
chri
butler
whenev
subcutisskin
specimen
test
one
possibl
subcutisskin
consist
mainli
adipos
tissu
cell
larg
comparison
nuclei
larg
storag
vacuol
cornifi
dermal
layer
cell
nuclei
may
plasmid
remain
deposit
portion
cell
ie
nucleu
outsid
cell
get
process
ie
express
degrad
consid
experi
address
phenomenon
one
concern
express
dna
plasmid
vaccin
possibl
might
integr
host
genom
given
im
integr
studi
provid
evid
integr
tissu
largest
amount
plasmid
inocul
profil
may
differ
deliveri
method
wang
et
al
one
benefit
conduct
studi
array
product
provid
eventu
effici
prepar
regulatori
submiss
provid
data
safeti
similar
pattern
biodistribut
variou
candid
vaccin
similar
observ
even
vaccin
differ
diseas
indic
built
similar
although
ident
plasmid
vaccin
platform
one
exampl
increas
effici
achiev
continu
bridg
biodistribut
newer
gener
product
initi
plasmid
vaccin
product
firstgener
prototyp
includ
arm
new
studi
comparison
product
permit
bridg
integr
studi
phase
clinic
safeti
data
obtain
time
regulatori
submiss
newer
candid
biodistribut
pattern
clearanc
pattern
newer
gener
product
seen
similar
product
even
anoth
diseas
indic
integr
studi
requir
repeat
candid
anoth
exampl
increas
effici
although
product
test
studi
go
forward
clinic
trial
studi
along
toxicolog
studi
product
describ
companion
articl
issu
support
conduct
clinic
trial
two
product
one
product
subset
product
consist
four
six
plasmid
product
anoth
sixplasmid
product
consist
three
plasmid
clade
b
c
env
gene
express
protein
three
plasmid
express
clade
b
gag
pol
nef
gene
separ
plasmid
rather
fusion
protein
newer
gener
sixplasmid
product
contain
differ
promot
cmvr
promot
origin
product
preclin
clinic
data
product
ebola
also
use
cmvr
promot
preclin
data
product
clinic
data
fourplasmid
product
support
regulatori
approv
current
sixplasmid
construct
without
repeat
preclin
biodistribut
repeateddos
toxicolog
studi
regulatori
effici
save
month
clinic
develop
pathway
new
candid
vaccin
given
urgenc
public
health
crise
hivaid
epidem
new
infect
daili
threat
global
spread
newli
emerg
viral
infect
like
sar
shorten
develop
time
crucial
design
studi
f
g
repres
refin
biodistribut
studi
perform
built
experi
prior
studi
well
guidanc
fda
meet
regulatori
requir
futur
biodistribut
studi
new
vaccin
candid
requir
studi
design
studi
like
follow
integr
studi
design
earli
develop
multitud
vaccin
candid
vrc
pipelin
might
repres
design
integr
studi
would
perform
today
addit
studi
requir
integr
studi
accept
fda
time
submit
support
conduct
clinic
trial
earli
vaccin
candid
well
subsequ
candid
bridg
back
data
primari
differ
would
introduc
futur
integr
studi
would
use
larger
speci
rabbit
dose
compar
human
dose
deliv
tissu
specimen
suffici
size
would
need
pool
order
get
suffici
amount
highmolecular
weight
dna
perform
analys
overal
conclud
studi
pattern
biodistribut
confin
site
inject
clearanc
within
month
dna
plasmid
vaccin
dose
mg
deliv
biojector
needl
syring
consist
regardless
differ
promot
plasmid
backbon
gene
express
plasmid
vaccin
cytokin
adjuv
thu
necessari
repeat
biodistribut
studi
newer
vaccin
candid
deliv
im
either
devic
studi
demonstr
theoret
safeti
concern
express
dna
plasmid
vaccin
eg
might
biodistribut
gonad
might
integr
born
vaccin
deliv
im
devic
data
studi
success
use
submiss
regulatori
agenc
us
fda
support
conduct
clinic
trial
number
vaccin
candid
differ
diseas
indic
wnv
sar
ebola
addit
biodistribut
integr
studi
build
data
acquir
companion
repeateddos
toxicolog
studi
see
companion
articl
issu
demonstr
safeti
vaccin
candid
suitabl
investig
human
use
